索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]骆颖琪,于涛,刘影.成纤维细胞激活蛋白抑制剂显像在心血管疾病中的研究进展[J].国际心血管病杂志,2023,06:354-357.
点击复制

成纤维细胞激活蛋白抑制剂显像在心血管疾病中的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年06期
页码:
354-357
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
-
作者:
骆颖琪; 于涛; 刘影
510260 广州医科大学附属第二医院核医学科（骆颖琪， 刘影）；610072 成都，四川省医学科学院· 四川省人民医院 电子 科技大学附属医院心脏外科中心（于涛）
Author(s):
-
关键词:
心血管疾病; 心肌损伤; 成纤维细胞激活蛋白; 成纤维细胞激活蛋白抑制剂
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.06.005
文献标识码:
-
摘要:
心肌慢性重构是心血管疾病的重要机制，心脏成纤维细胞（CF）在心肌重构中 发挥重要作用。成纤维细胞激活蛋白（FAP）特异性表达于CF，通过检测FAP 可早期识别 心脏损伤。成纤维细胞激活蛋白抑制剂（FAPI）可与FAP 靶向结合，不同放射性核素标记 的FAPI 可特异性识别和量化心肌纤维化。该文介绍FAPI 正电子发射断层显像（PET）在 心肌梗死、心力衰竭、肿瘤治疗相关心脏毒性和心肌病等心血管疾病中的应用以及FAPI 摄 取与心血管危险因素的关系。
Abstract:
-

参考文献/References

[1] 王增武, 胡盛寿. 中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治, 2022, 22(4):20-36.
[2] Pezel T, Viallon M, Croisille P, et al. Imaging interstitial fibrosis, left ventricular remodeling, and function in stage a and B heart failure[J]. JACC Cardiovasc Imaging, 2021, 14(5):1038-1052.
[3] Hoffmann DB, Fraccarollo D, Galuppo P, et al. Genetic ablation of fibroblast activation protein alpha attenuates left ventricular dilation after myocardial infarction[J]. PLoS One, 2021, 16(3):e0248196.
[4] Lyu Z, Han W, Zhao H, et al. A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease[J]. Front Cardiovasc Med, 2022, 9:921724.
[5] Song WY, Zhang X, He SK, et al. 68Ga-FAPI PET visualize heart failure: from mechanism to clinic[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2):475-485.
[6] Notohamiprodjo S, Nekolla SG, Robu S, et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04[J]. J Nucl Cardiol, 2022, 29(5):2254-2261.
[7] Lurz JA, Luecke C, Lang D, et al. CMR-derived extracellular volume fraction as a marker for myocardial fibrosis: the importance of coexisting myocardial inflammation[J]. JACC Cardiovasc Imaging, 2018, 11(1):38-45.
[8] Xu MX, Zhang P, Ding J, et al. Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy[J]. J Nucl Med, 2022, 63(6):952-958.
[9] Dahl K, Jussing E, Bylund L, et al. Fully automated production of the fibroblast activation protein radiotracer
[18F]FAPI-74[J]. J Labelled Comp Radiopharm, 2021, 64(8):346-352.
[10] Dorst DN, Rijpkema M, Buitinga M, et al. Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy[J]. Rheumatology (Oxford), 2022, 61(7):2999-3009.
[11] Luo YP, Pan QQ, Zhang W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2019, 46(12):2625-2626.
[12] Luo Y, Pan Q, Xu H, et al. Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5):1682-1683.
[13] Lin K, Chen X, Xue Q, et al. Diffuse uptake of
[68Ga]Ga-FAPI in the left heart in a patient with hypertensive heart disease by PET/CT[J]. J Nucl Cardiol, 2022, 29(6):3596-3598.
[14] Dorbala S. Fibroblast activation: a novel mechanism of heart failure in light chain cardiac amyloidosis?[J]. JACC Cardiovasc Imaging, 2022, 15(11):1971-1973.
[15] Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms , molecular pathways and therapeut ic opportunities[J]. Mol Aspects Med, 2019, 65: 70-99.
[16] Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Galabeled fibroblast activation protein inhibitor, FAPI-04[J]. J Nucl Med, 2019, 60(12):1743-1749.
[17] Diekmann J, Koenig T, Thackeray JT, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characterization and subsequent functional outcome[J]. J Nucl Med, 2022, 63(9): 1415-1423.
[18] Xie BQ, Wang JX, Xi XY, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8):2786-2797.
[19] Yuan TT, Wang XJ. 68Ga-FAPI PET/MRI in coronary heart disease[J]. J Nucl Cardiol, 2022, 29(6):3608-3610.
[20] Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart[J]. JACC Basic Transl Sci, 2019, 4(3):449-467.
[21] Zhang M, Quan WW, Zhu TQ, et al.
[68Ga]Ga-DOTA-FAPI-04 PET/Mr in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling[J]. Eur J Nucl Med Mol Imaging, 2023, 50(3):839-848.
[22] Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association[J]. Eur J Heart Fail, 2021, 23(3):352-380.
[23] Wang GK, Yang QQ, Wu SY, et al. Molecular imaging of fibroblast activity in pressure overload heart failure using
[68Ga]Ga-FAPI-04 PET/CT[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2):465-474.
[24] Totzeck M, Siebermair J, Rassaf T, et al. Cardiac fibroblast activation detected by positron emission tomography/ computed tomography as a possible sign of cardiotoxicity[J]. Eur Heart J, 2020, 41(9):1060.
[25] 权力, 张艳达, 赵健, 等. 化疗药物致心脏毒性的可能机制及 干预措施[J]. 国际心血管病杂志, 2021, 48(2):98-101.
[26] Jokar N, Amini A, Ravanbod M, et al. State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach[J]. Nucl Med Rev Cent East Eur, 2021, 24(2):82-92.
[27] Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of immune checkpoint inhibitors[J]. Curr Oncol Rep, 2021, 23(7):79.
[28] 裴华楠, 邵群, 张玲霞, 等. 免疫检查点抑制剂相关心肌炎的 诊治进展[J]. 国际心血管病杂志, 2022, 49(4):210-215.
[29] Kelly JM, Babich JW. PET tracers for imaging cardiac function in cardio-oncology[J]. Curr Cardiol Rep, 2022, 24(3):247-260.
[30] Finke D, Heckmann MB, Herpel E, et al. Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT[J]. Front Cardiovasc Med, 2021, 8:614997.
[31] Heckmann MB, Reinhardt F, Finke D, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease[J]. Circ Cardiovasc Imaging, 2020, 13(9):e010628.
[32] Brieler J, Breeden MA, Tucker J. Cardiomyopathy: an overview[J]. Am Fam Physician, 2017, 96(10):640-646.
[33] Wang L, Wang Y, Wang J, et al. Myocardial activity at 18F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy[J]. Radiology, 2023, 306(2):e221052.
[34] Cojan-Minzat BO, Zlibut A, Agoston-Coldea L. Non-ischemic dilated cardiomyopathy and cardiac fibrosis[J]. Heart Fail Rev, 2021, 26(5):1081-1101.
[35] Shi XM, Lin X, Huo L, et al. Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography[J]. J Nucl Cardiol, 2022, 29(2):881-884.
[36] Siebermair J, K?hler MI, Kupusovic J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling[J]. J Nucl Cardiol, 2021, 28(3):812-821.

备注/Memo

备注/Memo:
基金项目：四川省科技计划重点研发项目（2020YFQ0060）
通信作者：刘影， E-mail：liuying7999@126.com
更新日期/Last Update: 2023-11-20